Skip to main content

Table 1 Baseline patient characteristics and underlying malignancy

From: Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial

Age in years (range)

60.5

(30 - 81)

Gender

   Male

56

(64%)

   Female

31

(36%)

Baseline serum creatinine concentration in mg/dl (± SEM)

0.81

(± 0.28)

Arterial hypertension

21

(24%)

Concomitant nephrotoxic/volume depleting or blood pressure lowering medication

- NSAIDs

18 (21%)

 

- Loop diuretics

14 (16%)

 

- Thiazides

8 (9%)

 

- ACE inhibitor

6 (7%)

 

- AT2 blocker

4 (5%)

 

- Aldosterone antagonists

2 (2%)

 

Preceding chemotherapy

45 (52%)

 

Liver metastasis

45 (52%)

 
 

Group A (treated with capezitabine, rofecoxib and pioglitazone)

Group B (treated with trofosfamid, rofecoxib and pioglitazone)

Melanoma

 

16

Gastric carcinoma

13

 

Colorectal carcinoma

12

 

Renal cell carcinoma

9

 

Hepatic carcinoma/Klatskin

7

 

Sarcoma

 

5

Pulmonary adenocarcinoma/SCLC

 

3

Pancreatic cancer

3

 

Urothelium carcinoma

3

 

Gall bladder carcinoma

3

 

Breast cancer

 

2

Histiozytosis X

 

2

Hodgkin/Non-Hodgkin-Lymphoma

 

2

Ovarial carcinoma

 

2

TNE

 

2

Chronic lymphatic leukemia

 

1

Cervix carcinoma

 

1

  1. SCLC = small cell lung cancer; TNE = throat nose ear